Shots:

• NICE concludes that the ICER Yescarta vs salvage CT were above £50-000 per year making it expensive for use 
• NICE also added considering ultra-orphan diseases that ICER for Yescarta was over £100-000 per QALY (Quality Adjusted Life)
•  Consideration of making Yescarta available via Cancer Drug Funds has also been dropped by the committee. Consultation period for draft guidance runs until 18-Sep-2018

Ref: NICE| Image:  gilead